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Background. Diabetes is a major risk factor for skin and skin structure infection (SSSI), and the global burden of diabetics with 
SSSI is enormous. The more complex microbiology of diabetic foot infection (DFI) is well established, but it is not known whether 
microbiological etiology differs between diabetics and nondiabetics in other disease entities under the umbrella of complicated SSSI 
(cSSSI).
Methods. This retrospective, population-based study included patients with cSSSI, and it was conducted in 2 Nordic cities with 
a low prevalence of antimicrobial resistance. In analyses, patients (N = 460) were separated into 3 groups: diabetics (n = 119), non-
diabetics (n = 271), and patients with DFI (n = 70).
Results. After exclusion of patients with DFI, there was no difference in the microbiological etiology or initial antimicrobial 
treatment of cSSSI between diabetics and nondiabetics. Gram-positive bacteria encountered 70% of isolations in diabetics and 69% 
in nondiabetics, and the empirical treatment covered initial pathogens in 81% and 86% of patients, respectively. However, diabetes 
was the only background characteristic in the propensity score-adjusted analysis associated with broad-spectrum antimicrobial 
use and longer antibiotic treatment duration. Patients with DFI had Gram-negative and polymicrobial infection more often than 
nondiabetics.
Conclusions. These observations suggest that diabetics without DFI are not different in the causative agents of cSSSI, although 
they are more exposed to antimicrobial therapy of inappropriate extended spectrum and long duration. Broad-spectrum coverage 
was clearly needed only in DFI. A clear opportunity for antimicrobial stewardship was detected in the rapidly growing population 
of diabetic patients with cSSSI.
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The estimated prevalence of diabetes was 8.5% in the global 
adult population in 2014 [1]. In comparison to general popu-
lation, diabetics are more susceptible to a variety of infectious 
diseases, have more community-based antibiotic prescriptions, 
and also increased rate of hospitalization due to infection, 
including skin infections [2–4]. Skin and skin structure infec-
tion (SSSI) is generally regarded as complicated if it involves 
deep subcutaneous tissues, needs surgery in addition to anti-
microbial therapy, or affects a patient with severe comorbidities 
such as diabetes [5–8].
Gram-positive cocci, particularly streptococci and 
Staphylococcus aureus, are the major causative organisms of 
SSSI, but Gram-negative rods and anaerobic bacteria are fre-
quently detected in patients with diabetic foot infection (DFI) 
[8–10]. Therefore, broad-spectrum antimicrobial therapy 
that also covers Gram-negative infections is recommended 
by Infectious Diseases Society of America (IDSA) guidelines 
only in the treatment of moderate-to-severe DFI [11]. On the 
other hand, IDSA guidelines recommend antimicrobial ther-
apy targeted only to Gram-positive cocci in the treatment of 
(mild-to-moderate) cellulitis or abscess irrespective of the pres-
ence of diabetes [12].
Studies evaluating the microbiological etiology of SSSI 
(excluding DFI) separately among diabetics and nondiabetics 
are scarce. In a study including mostly patients with uncom-
plicated cellulitis or abscess, Gram-negative pathogens were 
not more common among diabetics than among nondiabetics 
[13]. Yet, the authors reported higher overall use of antibiotics 
with broad Gram-negative activity and also longer antimicro-
bial treatment duration in diabetics compared with nondia-
betics [13]. To the best of our knowledge, no population-based 
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comparative studies have been done between diabetics and 
nondiabetics with complicated SSSI (cSSSI).
In a population-based survey, we observed that diabetic 
patients with cSSSI had longer total duration of antimicrobial 
treatment than nondiabetics [14]. We wanted to further analyze 
the factors beyond this phenomenon, ie, possible differences in 
microbiological etiology and treatment practices between dia-
betics and nondiabetics in our population-based material col-
lected in 2 areas with low antimicrobial resistance.
MATERIALS AND METHODS
This was an observational retrospective cohort study, and inclu-
sion and exclusion criteria are described in more detail in the 
primary publication of this study [14]. The study population 
consisted of all adult residents from cities with nearly equal 
population (Helsinki, Finland population of 588 000 and the 
Gothenburg area, Sweden population 600 000) who were treated 
because of cSSSI during 2008–2011 in Helsinki University 
Central Hospital or Helsinki City Hospital in Finland and in 
Sahlgrenska University Hospital in Gothenburg, Sweden. These 
hospitals have the only emergency departments on their catch-
ment area and are thus responsible for treatment of almost all 
patients hospitalized with SSSIs. First selection was made by 
certain International Classification of Diseases, Tenth Revision 
diagnostic codes, and, to be included in the final analysis pop-
ulation (N = 460), patients were required to have an infection 
affecting deeper soft tissue, infection that required significant 
surgical intervention, developed on a lower extremity in a sub-
ject with diabetes mellitus or peripheral vascular disease, or to 
have a major abscess or infected ulcer. In addition to local signs 
of cSSSI, the patient also had to have at least 1 systemic sign 
of infection (temperature >38 or <36°C, white blood cell count 
>10 000/mm3 or <4000/mm3).
In the analyses, patients were divided into 3 separate groups: 
diabetics, nondiabetics, and patients with DFI. In our study, 
the definition of DFI was based on typical clinical presenta-
tion with infected (neuropathic) ulceration or (traumatic) 
wound, and due to requirement of systemic signs of infection, 
the DFIs in our study were classified as severe based on IDSA 
classification [11]. Presence of diabetes mellitus was based on 
medical records. Cellulitis or fasciitis was determined as lack 
of abscess, diabetic foot or leg ulcer, or peripheral vascular 
disease ulcer. The evaluation of clinical stability was based on 
improvement of vital signs and decreased fever, and treatment 
failure was defined as follows: need for unplanned surgery, no 
improvement in clinical situation after 5 days of treatment, or 
treatment failure registered in patient records by treating phy-
sician. Carbapenems and piperacillin-tazobactam were consid-
ered as broad-spectrum antimicrobial therapy in this analysis. 
Microbiological diagnosis was obtained by a bacterial culture 
of blood, tissue specimens, or superficial swabs in routine cul-
tures. In this analysis, coagulase-negative staphylococci and 
candida were not regarded as true pathogens. Data for evalu-
ation of recurrences and mortality were collected until 1-year 
post-cSSSI diagnosis.
Statistical Analysis
Results are presented as absolute values and percentages unless 
otherwise specified. Pearson’s χ2 test was applied to compare 
categorical variables, whereas Mann-Whitney U test was used 
for non-parametric data. Odds ratios (OR) with 95% confi-
dence intervals (CIs) were calculated. Univariate factors with 
P ≤ .1 were accepted for binary logistic regression multivariate 
analysis.
To verify the stability of the main results, a propensity score 
(PS) was calculated by logistic regression for the assignment of 
either (1) broad-spectrum or nonbroad-spectrum or (2) short 
(<17  days) or long (≥17  days) definitive antimicrobial treat-
ment. Variables interpreted as relevant for this assignment were 
age >60, chronic renal failure, respiratory disease, and injection 
drug abuse. Next, a PS-adjusted binary logistic regression multi-
variate analysis was performed to estimate treatment character-
istics specific for patients with a diagnosis of diabetes. All tests 
were 2-tailed and P < .05 was considered as significant. Analyses 
were done using SPSS version 21.0 (SPSS Inc., Chicago, IL).
RESULTS
In total, there were 460 patients with cSSSI, and the main com-
parison was performed between patients with diabetes (n = 119) 
and without it (n = 271), after the exclusion of 70 patients with 
DFI as a separate group. Diabetics were found to be signifi-
cantly older (mean age 71 [standard deviation {SD} = 15] vs 64 
[SD = 20] years; P = .001), and they more often had chronically 
elevated serum creatinine levels (13% vs 2%, median 182 vs 
333 µmol/L) or a respiratory disease (13% vs 6%), but they were 
less likely to be an injection drug abuser (1% vs 24%), compared 
with nondiabetics (Table 1). Diabetics were also found to have 
significantly more infection localized in the lower extremity 
(68% vs 49%, P  =  .001), classified as cellulitis (65% vs 43%), 
and they were likely to seek treatment earlier from the onset of 
symptoms (Table  1). Otherwise, diabetics did not differ from 
nondiabetics in their background or disease characteristics 
(Table 1).
Statistically significant differences were not found in ini-
tial microbiological etiology or initial antimicrobial therapy 
of cSSSI between diabetics and nondiabetics (Tables 2 and 3). 
However, broad-spectrum antimicrobial treatment was used 
more often in diabetics than in nondiabetics when the total 
period of antimicrobial treatment was analyzed: 42% vs 28%, 
respectively (OR 1.83, P = .008). Other factors associated with 
use of broad-spectrum therapy at any time during the course 
of treatment in multivariate analysis were as follows: invasive 
surgery within the previous 3  months (OR 2.79, P  =  .001), 
admission to intensive care unit ([ICU] OR 2.65, P  =  .001), 
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bacteremia (OR 2.55, P = .002), and polymicrobial etiology of 
infection (OR 3.76, P < .001). In contrast, staphylococcal infec-
tion was found to be inversely associated with broad-spectrum 
therapy in multivariate analysis (OR 0.37, P =  .001). Diabetes 
was the only background characteristic that was a risk factor for 
broad-spectrum therapy after PS-adjusted analysis (OR 1.75, 
P  =  .022). The initial bacterial pathogen was covered by the 
empirical antibiotic treatment in the vast majority of patients, 
and no significant difference was found between diabetics 
(81%) and nondiabetics (86%, P  =  .250). Gram-positive aer-
obic bacteria accounted for 70% and 69% of positive microbi-
ological diagnoses, and methicillin-resistant S aureus (MRSA) 
was detected in only 2% and 1% of patients with diabetes and 
without diabetes, respectively. Antimicrobial treatment with an 
agent covering MRSA was uncommon in our study; however, it 
was used in 0.4% and 4% of patients in initial and subsequent 
antibiotic treatment, respectively.
Patients without diabetes stabilized faster than diabetics 
(mean 3.9 vs 4.1 days) (Table 4) and were more likely to have 
surgical intervention conducted after diagnosis of cSSSI (57% vs 
44%; OR 1.31, P = .014). Total duration of antimicrobial treat-
ment differed significantly between diabetics and nondiabetics: 
the median of treatment duration was 21 days among diabetics 
and 14 days among nondiabetics (Table 4). Factors associated 
with longer (≥17  days) antibiotic treatment in multivariate 
analysis were as follows: diabetes (OR 1.71, P = .014), admission 
Table 1. Background and Disease Characteristics of Complicated Skin and Skin Structure Infections Among Diabetics, Nondiabetics, and Patients With 
Diabetic Foot Infection (N = 460)a
Patient or Disease Characteristic
Patients With 
Diabetes
(n = 119)
Patients Without 
Diabetes
(n = 271)
Diabetics vs Nondiabetics
Diabetic Foot 
Infection (n = 70)
Diabetic Foot Infection vs 
Nondiabetics
OR (95% CI) Pb OR (95% CI) Pb
Male gender 70 (59) 157 (58) 1.04 (0.67–1.61) .870 53 (76) 2.26 (1.25–4.11) .006
Age >60 years 93 (78) 149 (55) 2.93 (1.78–4.81) <.001 58 (83) 3.96 (2.03–7.70) <.001
HIV infection 3 (3) 4 (1) 1.73 (0.38–7.84) .474 0 (0) 0.99 (0.97–1.00) .307
Any disease with immune sys-
tem impairment
3 (3) 10 (4) 0.68 (0.18–2.50) .554 1 (1) 0.38 (0.05–3.01) .340
Cancer/malignancy 10 (8) 22 (8) 1.04 (0.48–2.27) .925 4 (6) 0.69 (0.23–2.06) .499
Chronic renal failure 15 (13) 6 (2) 6.37 (2.41–16.9) <.001 11 (16) 8.23 (2.93–23.2) <.001
Congestive heart disease 10 (8) 25 (21) 0.90 (0.42–1.94) .794 8 (11) 1.27 (0.55–2.95) .578
Liver disease 4 (3) 16 (6) 0.55 (0.18–1.70) .295 3 (4) 0.71 (0.20–2.52) .599
Peripheral vascular disease 32 (27) 67 (25) 1.12 (0.69–1.83) .651 36 (51) 3.22 (1.87–5.55) <.001
Respiratory disease 16 (13) 17 (6) 2.32 (1.13–4.77) .019 1 (1) 0.22 (0.03–1.66) .106
Alcohol abuse 6 (5) 25 (21) 0.52 (0.21–1.31) .160 9 (13) 1.45 (0.65–3.27) .366
Injection drug abuse 1 (1) 29 (24) 0.07 (0.01–0.53) .001 2 (3) 0.25 (0.06–1.06) .042
Hospitalization within previous 
3 months
30 (25) 50 (42) 1.49 (0.89–2.49) .128 4 (6) 0.27 (0.09–0.77) .009
Invasive surgery within previous 
3 months
23 (19) 47 (17) 1.14 (0.66–1.99) .638 1 (1) 0.07 (0.01–0.51) .001
Treatment with antibiotics 
before diagnosis of cSSSI
25 (21) 72 (27) 0.74 (0.44–1.23) .242 31 (44) 2.20 (1.28–3.78) .004
Abscess 42 (35) 124 (46) 0.65 (0.41–1.01) .054 17 (24) 0.38 (0.21–0.69) .001
Cellulitis/fascitis 77 (65) 116 (43) 2.45 (1.57–3.83) <.001 0 (0) 0.57 (0.52–0.63) <.001
Postsurgical wound 29 (24) 48 (18) 1.50 (0.89–2.52) .128 2 (3) 0.14 (0.03–0.58) .002
Posttraumatic wound 10 (8) 37 (14) 0.58 (0.28–1.21) .143 3 (4) 0.28 (0.09–0.95) .030
Number of Days Between Symptoms Start and Diagnosis
 <2 days 50 (42) 74 (27) 1.93 (1.23–3.03) .004 6 (9) 0.25 (0.10–0.60) .001
 2–7 days 53 (45) 139 (51) 0.76 (0.50–1.18) .219 38 (54) 1.13 (0.67–1.91) .655
 >7 days 16 (13) 50 (18) 0.69 (0.37–1.26) .225 24 (34) 2.31 (1.29–4.12) .004
 Unknown 0 (0) 8 (3) 0.97 (0.95–0.99) .058 2 (3) 0.97 (0.20–4.66) .967
Highest C-reactive protein level 
(n = 451, mean [SD])
240 (116) 222 (140) .056c 192 (97) .291c
Bacteremia 18 (15) 34 (13) 1.24 (0.67–2.30) .490 9 (13) 1.03 (0.47–2.26) .944
Septic shock 2 (2) 6 (5) 0.76 (0.15–3.80) .732 0 (0) 0.98 (0.96–1.00) .209
Admitted to ICU 15 (13) 52 (19) 0.61 (0.33–1.13) .113 6 (9) 0.40 (0.16–0.96) .035
Abbreviations: CI, confidence interval; cSSSI, complicated skin and skin structure infection; HIV, human immunodeficiency virus; ICU intensive care unit; OR, odds ratio; SD, standard 
deviation. 
aData are no. (%) of patients unless otherwise specified.
bPearson’s χ2 test.
cMann-Whitney U test.
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to ICU (OR 2.96, P  <  .001), chronic renal failure (OR 2.85, 
P = .024), polymicrobial infection etiology (OR 2.27, P = .003), 
infection localized to lower extremity (OR 2.11, P  =  .001), 
and short (<2  days) duration of symptoms before diagno-
sis of cSSSI (OR 1.86, P  =  .006). Background characteristics 
that differed significantly in univariate analysis were included 
in the PS-adjusted analysis, in which only diabetes (OR 1.99, 
P  =  .004) was detected to be statistically significantly associ-
ated with longer (≥17 days) antimicrobial treatment duration. 
There was no difference in 30-day mortality, clinical failure rate, 
Table 3. Initial Antimicrobial Agents in the Treatment of Complicated Skin and Skin Structure Infections Among Diabetics, Nondiabetics, and Patients 
With Diabetic Foot Infection (N = 458)a
Antimicrobial Agent
Patients With Diabetes 
(n = 118)
Patients Without 
Diabetes (n = 270)
Diabetics vs 
Nondiabetics
Diabetic Foot Infection 
(n = 70)
Diabetic Foot Infection 
vs Nondiabetics
OR (95% CI) Pb OR (95% CI) Pb
Broad-spectrumc 26 (22) 39 (14) 1.67 (0.96–2.91) .066 21 (30) 2.54 (1.37–4.69) .002
Cephalosporinsd 60 (51) 133 (49) 1.07 (0.69–1.64) .773 31 (44) 0.82 (0.48–1.39) .458
Othere 11 (9) 31 (11) 0.79 (0.38–1.64) .529 2 (3) 0.23 (0.05–0.97) .030
Penicillinsf 12 (10) 29 (11) 0.94 (0.46–1.91) .866 11 (16) 1.55 (0.73–3.28) .250
Penicillins with staphylococcal 
effectg
9 (8) 38 (14) 0.50 (0.24–1.08) .073 5 (7) 0.47 (0.18–1.24) .120
Abbreviations: CI, confidence interval; OR, odds ratio.
aData are no. (%) of patients unless otherwise specified.
bPearson’s χ2 test.
cCarbapenem and piperacillin-tazobactam. 
dCefadroxil, cefotaxim, ceftriaxone, cefuroxime, and cephalexin.
eClindamycin, doxycyclin, fluoroquinolone, fusidic acid, linezolid, metronidazole, cotrimoxazole, tobramycin, and vancomycin. 
fAmoxicillin, benzylpenicillin, and phenoxymethylpenicillin. 
gCloxacillin, flucloxacillin, and other β-lactamase-stable penicillins.
Table 2. Microbiological Diagnosis of Complicated Skin and Skin Structure Infections Among Diabetics, Nondiabetics, and Patients With Diabetic Foot 
Infection (N = 460)a
Microbiological Diagnosis
Patients With Diabetes 
(n = 119)
Patients Without 
Diabetes (n = 271)
Diabetics vs 
Nondiabetics
Diabetic Foot 
Infection (n = 70)
Diabetic Foot Infection 
vs Nondiabetics
OR (95% CI) Pb OR (95% CI) Pb
Staphylococci 27 (23) 77 (28) 0.74 (0.45–1.22) .239 9 (13) 0.37 (0.18–0.79) .008
 Methicillin-sensitive 
Staphylococcus aureus
26 (22) 75 (28) 8 (11)
 Methicillin-resistant S aureus 1 (1) 2 (1) 1 (1)
Streptococci 27 (23) 67 (25) 0.89 (0.54–1.49) .665 11 (16) 0.57 (0.28–1.14) .110
 Streptococcus pyogenes 8 (7) 46 (17) 0 (0)
 Streptococcus agalactiae 4 (3) 2 (1) 2 (3)
 β-hemolytic streptococci 14 (12) 8 (3) 9 (13)
 Streptococcus pneumoniae 1 (1) 2 (1) 0 (0)
 α-hemolytic streptococci 0 (0) 9 (3) 0 (0)
Gram-negative bacteria 8 (7) 13 (5) 1.43 (0.58–3.55) .438 9 (13) 2.93 (1.20–7.16) .014
 Enterobacteriacae 5 (4) 8 (3) 6 (9)
 Pseudomonas 3 (3) 2 (1) 0 (0)
 Other Gram-negative bacteria 0 (0) 3 (1) 3 (4)
Other microorganism 3 (3) 10 (4) 0.68 (0.18–2.50) .554 1 (1) 0.38 (0.05–3.01) .340
 Anaerobic bacteria 2 (2) 8 (3) 0 (0)
 Enterococci 1 (1) 2 (1) 1 (1)
Polymicrobial infections 19 (16) 45 (17) 0.95 (0.53–1.71) .875 22 (31) 2.30 (1.27–4.18) .005
 Only Gram-positive bacteria 4 (3) 19 (7) 8 (11)
 Only Gram-negative bacteria 0 (0) 1 (0) 2 (3)
 Mixed 15 (13) 25 (9) 12 (17)
Negative/unknown 35 (29) 59 (22) 1.50 (0.92–2.44) .104 18 (26) 1.24 (0.68–2.29) .482
Abbreviations: CI, confidence interval; OR, odds ratio.
aData are no. (%) of patients unless otherwise specified.
bPearson’s β2 test.
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or rehospitalization rate between diabetics and nondiabetics 
(Table 4).
Patients with DFI were compared separately with nondia-
betic patients, and they had staphylococcal infection less often 
and Gram-negative or polymicrobial infections more often 
than nondiabetics (Table  2). Accordingly, patients with DFI 
had broad-spectrum antimicrobial as initial therapy more often 
than patients without diabetes (Table 3). The median duration 
of antimicrobial treatment and hospital stay was longer among 
patients with DFI than nondiabetics, 21 vs 14 days and 14 vs 
10 days, respectively (Table 4). However, patients with DFI had 
more recurrences than nondiabetics: 26% of patients with DFI 
and 14% of patients without diabetes were hospitalized again 
due to cSSSI (Table 4).
DISCUSSION
In our population-based study, a statistically significant dif-
ference was not detected between nondiabetics and diabetics 
without DFI in the microbiological etiology of cSSSI. However, 
compared with nondiabetics, diabetics without DFI were 
treated more often with broad-spectrum antimicrobial therapy, 
and their antimicrobial treatment also continued for a longer 
time period.
Diabetics constituted 37% of our patient population and 35% 
of patients hospitalized due to cSSSI in an American study, indi-
cating that diabetes is clearly one of the main risk factors for 
cSSSI [7]. Diabetic patients have differed from nondiabetics in 
many aspects both in our cSSSI population and previous studies 
with less severe SSSI [13, 15–17]. Diabetics have been older, 
more likely to have infection classified as cellulitis or infection 
localized into a lower extremity, and had chronic renal failure 
more often but less injection drug abuse [13, 15–17]. However, 
in our study, no statistically significant differences were detected 
between diabetics and nondiabetics in the objective markers of 
disease severity (C-reactive protein [CRP] level or rate of bac-
teremia, septic shock, or admission to ICU). It is possible that 
diabetic patients had been educated to seek treatment earlier or 
had easier access to their primary care physician and were also 
send more often to hospital evaluation than nondiabetics.
More importantly, statistically significant differences in the 
microbiological etiology between diabetics and nondiabetics 
were not found in cSSSI in our study nor in SSSI in the study 
by Jenkins et al [13]. In our study, Gram-positive aerobic bacte-
ria accounted for the vast majority of microbiological diagno-
sis (diabetics 70% and nondiabetics 69%), which is consistent 
with the study by Jenkins et  al [13] and also to other studies 
in patients with cSSSI [7, 8, 18, 19]. In light of this finding, the 
observation of more frequent use of broad-spectrum antibiot-
ics among diabetics in our study and in the study by Jenkins 
et al [13] is remarkable. More frequent broad-spectrum use was 
not observed in either study in the empirical antibiotic choice, 
but the antibiotics were changed to broad-spectrum more often 
among diabetics than in nondiabetics. We found that diabetics 
have later treatment response than nondiabetics, which can also 
explain why diabetics had their antibiotic treatment escalated to 
broad-spectrum therapy more often than nondiabetics. Many 
Table 4. Clinical Outcomes and the Use of Resources of Complicated Skin and Skin Structure Infections Among Diabetics, Nondiabetics, and Patients 
With Diabetic Foot Infectiona
Outcome
Patients With 
Diabetes
Patients Without 
Diabetes
Diabetics vs Nondiabetics
Diabetic Foot 
Infection
Diabetic Foot Infection vs 
Nondiabetics
OR (95% CI) P OR (95% CI) P
Clinical failure due to cSSSI (n = 457) 31 (26) 56 (21) 1.33 (0.81–2.21) .262b 19 (27) 1.41 (0.77–2.58) .263b
Hospitalized again due to cSSSI 
(n = 439)
16 (13) 38 (14) 0.93 (0.50–1.75) .825b 18 (26) 2.12 (1.12–4.02) .020b
Mortality 30 days (n = 460) 6 (5) 11 (4) 1.26 (0.45–3.48) .662b 2 (3) 0.70 (0.15–3.21) .640b
Mortality 12 months (n = 451) 23 (19) 25 (9) 2.35 (1.27–4.34) .005b 5 (7) 0.75 (0.28–2.04) .571b
Time to clinical stability, days 
(n = 402, mean [SD])
4.1 (3.5) 3.9 (4.2) .038c 4.1 (4.3) .133c
Total duration of antibiotic treatment, 
days (n = 448, median [IQR25, 
IQR75])
21 (12–38) 14 (8–28) <.001c 21 (10–40) .005c
Number of different antibiotic therapy 
courses (n = 457, mean [SD])
3.6 (2.2) 3.3 (1.9) .560c 3.8 (2.7) .368c
Length of hospital stay, days 
(n = 416, median [IQR25, IQR75])
13 (6–21) 10 (5–20) .090c 14 (8–26) .006c
Number of clinics during hospital stay 
(n = 460, mean [SD])
1.7 (1.0) 1.5 (1.0) .022c 1.9 (1.5) .078c
Abbreviations: CI, confidence interval; cSSSI, complicated skin and skin structure infection; IQR, interquartile range; OR, odds ratio; SD, standard deviation. 
aData are no. (%) of patients unless otherwise specified.
bPearson’s χ2 test.
cMann-Whitney U test.
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newer broad-spectrum antibiotics are officially indicated for the 
treatment of cSSSI, and these are actively studied and marketed 
[16]. The extent to which this might have affected the treatment 
choices in our study cannot be answered.
Our results in cSSSI and those of Jenkins et al [13] in SSSI 
support the current treatment recommendations. In the treat-
ment of cellulitis or an abscess, IDSA guidelines recommend 
antimicrobial treatment that covers staphylococci and strepto-
cocci, irrespective of the presence of diabetes. Broad-spectrum 
empirical antimicrobial therapy is only recommended for the 
most severe forms of SSSI (Figure  1) [12]. Our findings sug-
gests that empirical broad-spectrum therapy could also be 
streamlined to narrow-spectrum therapy in cSSSI in diabetics, 
although it has been noticed that streamlining rarely happens 
in real life [8, 14].
The third main observation of this study also correlates with 
the results by Jenkins et  al [13] that antimicrobial treatment 
lasts longer in diabetics than in nondiabetics. In our study, the 
median total duration of antimicrobial treatment was 21 days 
in diabetics and 14 days in nondiabetics, compared to 13 and 
12 days detected by Jenkins et al [13], respectively. Because the 
severity of infection was not similar in these studies, the total 
treatment durations cannot be compared between them. The 
slightly longer time (0.2 days) to clinical stability among dia-
betics might partially explain the longer antibiotic treatment. 
However, no difference was not found in the length of hospital 
stay between diabetics and nondiabetics. This means that the 
difference in the duration of antimicrobial treatment mainly 
reflects antibiotics prescribed at the time of discharge from 
hospital. In comparison with nondiabetics, diabetics were more 
often transferred between departments during their hospital 
stay, a factor that may also have an impact on their longer dura-
tion of antimicrobial treatment.
Diabetic foot infection comprised only 15% of our patients. 
Diabetic foot infection was separated from other cSSSIs among 
diabetics in the analyses, and DFI seems to differ substantially 
from cSSSI among nondiabetics. Patients with DFI had less 
staphylococci and more Gram-negative or polymicrobial infec-
tions than nondiabetics with cSSSI, and their treatment was 
started more often with a broad-spectrum antibiotic. Moreover, 
our data support the IDSA guidelines, which recommend the 
use of broad-spectrum antibiotic in empirical therapy only in 
moderate-to-severe DFI (Figure 1) [11]. Our patients with DFI 
would be classified as severe because signs of systemic infection 
were required. In addition, patients with DFI had more recur-
rences, longer median time of hospital stay, and longer total 
antimicrobial treatment duration than nondiabetics. The defini-
tion of DFI in our study can be questioned, yet the classification 
of infection was made by 2 experienced clinicians who collected 
the data and ended up with similar proportions of DFI between 
the study centers (Helsinki, 32 of 219; Gothenburg, 37 of 241). 
Minority of infections in the lower extremities of diabetics were 
classified as DFI in our study. In theory, the inclusion criteria of 
our study may have allowed patients with diabetes (or peripheral 
arterial disease) with less severe infections of lower extremities 
to be included; however, no statistically significant difference 
Diabetic patient
with a skin and soft
tissue infection
Diabetic patient
without DFI
Diabetic patient
with DFI
Mild Moderate Severe Severe
Empirical antimicrobial treatment targeted also
to Gram-negative (and anaerobic) bacteria
Empirical antimicrobial treatment targeted
only to Gram-positive bacteria
Moderate Mild
Figure 1. Suggested algorithm for empirical treatment of a skin and soft tissue infection in diabetic patients. Modified from Infectious Diseases Society of America guide-
lines [11, 12] and supported by our study data. DFI, diabetic foot infection.
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was detected in the level of highest CRP value between patients 
with DFI and nondiabetics with cSSSI. On the basis of above 
facts, it can be stated that the patients with DFI in our study 
shared similarities with the DFI patients in general [10, 20–22] 
and, on the other hand, differed from the diabetics without DFI 
in our study.
The high affinity of people to public healthcare in Nordic 
countries enabled the population-based approach used in this 
study. We also considered the low prevalence of MRSA in Nordic 
countries (2011: 2.8% in Finland and 0.8% in Sweden) to be a 
strength of the study by eliminating 1 possible confounding fac-
tor [23, 24]. The data were collected in 2 countries, which makes 
it more generalizable. The weaknesses of our retrospective study 
included its complete dependence on clinical patient records, 
which were not initially made for research purposes, and lack 
of evaluation of glycemic control. Furthermore, microbiologi-
cal diagnosis was mainly based on superficial swabs, which may 
also detect bacterial colonization in addition to causative micro-
biological agents. It is possible that this did not lead to bias in 
intergroup analyses; however, prospective studies with invasive 
microbiological sampling in diabetics with cSSSI are needed. 
Furthermore, patients with severe conditions, compared with 
patients with an optimistic prognosis, were probably more likely 
receive broad-spectrum antimicrobial treatment. This phenom-
ena of “confounding by indication” is a further source for bias 
in our retrospective cohort analyses [25]. Propensity score- 
adjusted analyses may reduce the potential bias associated with 
retrospective analyses [26]. The main results of the present study 
were observed in PS-adjusted analysis, correcting for significant 
differences between diabetics and nondiabetics.
CONCLUSIONS
In conclusion, after exclusion of patients with diabetic foot 
infection, no statistically significant differences in the micro-
biological etiology of cSSSI were found between diabetics and 
nondiabetics. However, diabetics were treated significantly 
more often than nondiabetics with broad-spectrum antibiotics 
covering Gram-negative and anaerobic bacteria, and their anti-
biotic treatment lasted longer than the treatment for patients 
without diabetes. These observations offer a clear opportunity 
for antimicrobial stewardship in the vulnerable, ever-growing 
population of diabetic patients.
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